Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Roflumilast - AstraZeneca

Drug Profile

Roflumilast - AstraZeneca

Alternative Names: APTA-2217; B 9302-107; BY 217; BYK 20869; Daliresp; Daxas; IN-ALR 01; Libertek

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ALTANA Pharma
  • Developer Actavis; Almirall S.A.; ALTANA Pharma; AstraZeneca; Mitsubishi Tanabe Pharma Corporation; Takeda; Takeda Pharmaceuticals International GmbH
  • Class Aminopyridines; Anti-inflammatories; Antiallergics; Antiasthmatics; Antipsoriatics; Benzamides; Chlorinated hydrocarbons; Cyclopropanes; Fluorinated hydrocarbons; Skin disorder therapies; Small molecules
  • Mechanism of Action Type 4 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Chronic obstructive pulmonary disease
  • Discontinued Alzheimer's disease; Asthma; Atopic dermatitis; Non-alcoholic steatohepatitis; Plaque psoriasis; Schizophrenia; Type 2 diabetes mellitus

Most Recent Events

  • 27 Jul 2022 No development reported - Phase-III for Chronic obstructive pulmonary disease (Combination therapy) in Spain, United Kingdom, Austria (PO) (AstraZeneca website, July 2022) (ALTANA Pharma website, July 2022)
  • 08 May 2020 Allergan has been acquired and merged into AbbVie
  • 23 Jul 2018 Roflumilast licensed to Acrutis Biotherapeutics worldwide for the treatment of Plaque psoriasis and Atopic dermatitis
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top